Construction of an Anti-IL-1&bgr; scfv and TNFRI Fusion Protein and Its Therapeutic Effect on RA Mice Model

E-ISSN： 1873-4316|14|12|1048-1061

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.14, Iss.12, 2013-11, pp. : 1048-1061

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anabolic Steroid - and Exercise - Induced Cardio-Depressant Cytokines and Myocardial &bgr;1 Receptor Expression in CD1 Mice

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 2, 2011-02 ,pp. : 275-284

Bentham Science Publishers

Access to resources Recommend Favorite

TGF-&bgr;: Its Role in Asthma and Therapeutic Potential

Current Drug Targets, Vol. 7, Iss. 5, 2006-05 ,pp. : 547-565

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes

Current Pharmaceutical Design, Vol. 17, Iss. 29, 2011-10 ,pp. : 3224-3228

Bentham Science Publishers

Access to resources Recommend Favorite

The Amyloid &bgr;-Protein Precursor and Alzheimer's Disease. Therapeutic Approaches

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 5, Iss. 4, 2005-12 ,pp. : 271-283

Bentham Science Publishers

Access to resources Recommend Favorite

TGF-&bgr;, Eosinophils and IL-13 in Allergic Airway Remodeling: A Critical Appraisal with Therapeutic Considerations

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 7, Iss. 4, 2008-12 ,pp. : 224-236

Bentham Science Publishers

Access to resources Recommend Favorite